SCHEDULE 13G/A: Soleus Capital Group Discloses 9.9% Stake in Organogenesis Holdings Inc.
Schedule 13G Filing
Soleus Capital Master Fund, L.P. and its affiliated entities, including Guy Levy, have reported a collective beneficial ownership of 9.9% in Organogenesis Holdings Inc., totaling 12,484,876 shares.
Summary
- Soleus Capital Master Fund, L.P., along with Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy, collectively reported beneficial ownership of 12,484,876 shares of Organogenesis Holdings Inc. common stock.
- This aggregate ownership represents 9.9% of Organogenesis Holdings Inc.'s outstanding common stock.
- The percentage is calculated based on 125,725,796 shares of common stock outstanding as of December 11, 2024, as reported in the Issuer's Prospectus dated December 20, 2024.
- All reporting persons hold shared voting and shared dispositive power over the 12,484,876 shares, with no sole voting or dispositive power.
- The shares are held directly by Soleus Capital Master Fund, L.P., with the other entities and Guy Levy disclaiming beneficial ownership except for Section 13(d) purposes.
- The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant passive ownership stake by an investment fund in a publicly traded company. It does not provide specific insights into broader industry trends or competitive positioning, but rather reflects an investment decision by Soleus Capital in the healthcare/biotechnology sector where Organogenesis operates.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant ownership stake held by Soleus Capital and its affiliates, which could be viewed as a vote of confidence or a potential precursor to future engagement, though the filing states a passive investment intent.
Key Dates
| Date | Description |
|---|---|
| 2024-12-11 | Date as of which 125,725,796 shares of common stock of Organogenesis Holdings Inc. were outstanding, used for percentage calculation. |
| 2024-12-20 | Date of Organogenesis Holdings Inc.'s Prospectus. |
| 2024-12-23 | Date Organogenesis Holdings Inc.'s Prospectus was filed with the SEC. |
| 2024-12-31 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-02-11 | Date of signing for the Schedule 13G filing. |
Keywords
Organogenesis Holdings Inc., Soleus Capital Master Fund, Soleus Capital, Guy Levy, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Equity Stake, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.